Thursday, March 24, 2016

BRIEF-Axsome Therapeutics reports Q4 loss per share of $0.12

* "currently anticipates that its cash will be sufficient to fund its anticipated operations into q3 of 2017"


Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)